Search

Your search keyword '"Johnson, Nathalie A."' showing total 790 results
Start Over Author "Johnson, Nathalie A."
790 results on '"Johnson, Nathalie A."'

1. Identification of genetic subtypes in follicular lymphoma

Author

Shelton, Victoria, Detroja, Rajesh, Liu, Ting, Isaev, Keren, Silva, Anjali, Passerini, Verena, Bakhtiari, Mehran, Calvente, Lourdes, Hong, Michael, He, Michael Y., Modi, Saloni, Hershenfeld, Samantha A., Ludvigsen, Maja, Madsen, Charlotte, Hamilton-Dutoit, Stephen, d’Amore, Francesco Annibale, Brodtkorb, Marianne, Johnson, Nathalie A., Baetz, Tara, LeBrun, David, Tobin, Josh W. D., Gandhi, Maher K., Mungall, Andrew J., Xu, Wei, Ben-Neriah, Susana, Steidl, Christian, Delabie, Jan, Tremblay-LeMay, Rosemarie, Jegede, Opeyemi, Weigert, Oliver, Kahl, Brad, Evens, Andrew M., and Kridel, Robert

Published
2024
Full Text
View/download PDF

3. STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment

Author

Benoit, Alexandre, Abraham, Madelyn J., Li, Sheena, Kim, John, Estrada-Tejedor, Roger, Bakadlag, Rowa, Subramaniam, Nivetha, Makhani, Kiran, Guilbert, Cynthia, Tu, Raymond, Salaciak, Matthew, Klein, Kathleen Oros, Coyle, Krysta Mila, Hilton, Laura K., Santiago, Raoul, Dmitrienko, Svetlana, Assouline, Sarit, Morin, Ryan D., del Rincon, Sonia V., Johnson, Nathalie A., and Mann, Koren K.

Published
2024
Full Text
View/download PDF

5. Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysisImpact of B-cell malignancy therapy on COVID-19 outcomes

Author

Rubinstein, Samuel M, Bhutani, Divaya, Lynch, Ryan C, Hsu, Chih-Yuan, Shyr, Yu, Advani, Shailesh, Mesa, Ruben A, Mishra, Sanjay, Mundt, Daniel P, Shah, Dimpy P, Sica, R Alejandro, Stockerl-Goldstein, Keith E, Stratton, Catherine, Weiss, Matthias, Beeghly-Fadiel, Alicia, Accordino, Melissa, Assouline, Sarit E, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bilen, Mehmet Asim, Castellano, Cecilia A, Cogan, Jacob C, Kc, Devendra, Friese, Christopher R, Gupta, Shilpa, Hausrath, Daniel, Hwang, Clara, Johnson, Nathalie A, Joshi, Monika, Kasi, Anup, Klein, Elizabeth J, Koshkin, Vadim S, Kuderer, Nicole M, Kwon, Daniel H, Labaki, Chris, Latif, Tahir, Lau, Eric, Li, Xuanyi, Lyman, Gary H, McKay, Rana R, Nagaraj, Gayathri, Nizam, Amanda, Nonato, Taylor K, Olszewski, Adam J, Polimera, Hyma V, Portuguese, Andrew J, Puc, Matthew M, Razavi, Pedram, Rosovski, Rachel, Schmidt, Andrew, Shah, Sumit A, Shastri, Aditi, Su, Christopher, Torka, Pallawi, Wise-Draper, Trisha M, Zubiri, Leyre, Warner, Jeremy L, and Thompson, Michael A

Subjects
Rare Diseases, Clinical Research, Prevention, Cancer, Aetiology, 2.1 Biological and endogenous factors, COVID-19, COVID-19 Testing, Humans, Lymphatic Diseases, Neoplasms, Risk Factors, SARS-CoV-2, COVID-19 and Cancer Consortium
Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.SignificanceOur study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.

Published
2022

8. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

Author

Armand, Philippe, Zinzani, Pier Luigi, Lee, Hun Ju, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Herrera, Alex F., Lin, Jianxin, Kim, Eunhee, Chakraborty, Samhita, Marinello, Patricia, and Moskowitz, Craig H.

Published
2023
Full Text
View/download PDF

10. A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie A., additional, Avigdor, Abraham, additional, Peter, Borchmann, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth P., additional, Keane, Colm, additional, Torzan, Inna, additional, Vucinic, Vladan, additional, Zinzani, Pier Luigi, additional, West, Rachel Marceau, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Herrera, Alex Francisco, additional

Published
2024
Full Text
View/download PDF

14. Analysis by TeloView ® Technology Predicts the Response of Hodgkin's Lymphoma to First-Line ABVD Therapy.

Author

Knecht, Hans, Johnson, Nathalie, Bienz, Marc N., Brousset, Pierre, Memeo, Lorenzo, Shifrin, Yulia, Alikhah, Asieh, Louis, Sherif F., and Mai, Sabine

Subjects
*VINBLASTINE, *MEDICAL technology, *PREDICTION models, *RECEIVER operating characteristic curves, *CANCER relapse, *RESEARCH funding, *LOGISTIC regression analysis, *TREATMENT effectiveness, *MULTIVARIATE analysis, *DESCRIPTIVE statistics, *BLEOMYCIN, *DOXORUBICIN, *DACARBAZINE, *TELOMERES, *PROGRESSION-free survival, *HODGKIN'S disease, *SENSITIVITY & specificity (Statistics), *DISEASE progression, *DISEASE risk factors
Abstract

Simple Summary: Three-dimensional (3D) telomere analysis using TeloView v 2.2 has shown promise in quantifying genomic instability and predicting therapy response. In a study of 156 Classic Hodgkin's lymphoma (cHL), we identified significant 3D telomere parameters that predict patient outcomes. A predictive model using four 3D telomere parameters, including the proportion of t-stumps (very short telomeres), achieved an area under curve (AUC) of 0.83, with a sensitivity and specificity of 0.82 and 0.78, respectively. Classic Hodgkin's lymphoma (cHL) is a curable cancer with a disease-free survival rate of over 10 years. Over 80% of diagnosed patients respond favorably to first-line chemotherapy, but few biomarkers exist that can predict the 15–20% of patients who experience refractory or early relapsed disease. To date, the identification of patients who will not respond to first-line therapy based on disease staging and traditional clinical risk factor analysis is still not possible. Three-dimensional (3D) telomere analysis using the TeloView® software platform has been shown to be a reliable tool to quantify genomic instability and to inform on disease progression and patients' response to therapy in several cancers. It also demonstrated telomere dysfunction in cHL elucidating biological mechanisms related to disease progression. Here, we report 3D telomere analysis on a multicenter cohort of 156 cHL patients. We used the cohort data as a training data set and identified significant 3D telomere parameters suitable to predict individual patient outcomes at the point of diagnosis. Multivariate analysis using logistic regression procedures allowed for developing a predictive scoring model using four 3D telomere parameters as predictors, including the proportion of t-stumps (very short telomeres), which has been a prominent predictor for cHL patient outcome in a previously published study using TeloView® analysis. The percentage of t-stumps was by far the most prominent predictor to identify refractory/relapsing (RR) cHL prior to initiation of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy. The model characteristics include an AUC of 0.83 in ROC analysis and a sensitivity and specificity of 0.82 and 0.78 respectively. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Author

Zinzani, Pier Luigi, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A., de Oliveira, Jose S.R., Buccheri, Valeria, Perini, Guilherme Fleury, Dickinson, Michael, McDonald, Andrew, Özcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Raut, Monika, Saretsky, Todd L., Nahar, Akash, and Kuruvilla, John

Published
2022
Full Text
View/download PDF

16. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

Author

Zinzani, Pier Luigi, primary, Salles, Gilles A., additional, Moskowitz, Alison J, additional, Santoro, Armando, additional, Mehta, Amitkumar, additional, Barr, Paul M., additional, Mehta-Shah, Neha, additional, Collins, Graham P., additional, Ansell, Stephen M., additional, Brody, Joshua D., additional, Domingo-Domenech, Eva, additional, Johnson, Nathalie A., additional, Cunningham, David, additional, Ferrari, Silvia, additional, Lisano, Julie M, additional, Krajewski, Jennifer, additional, Wen, Rachael, additional, Akyol, Alev, additional, Crowe, Russell, additional, and Savage, Kerry J., additional

Published
2024
Full Text
View/download PDF

17. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Author

Kuruvilla, John, Ramchandren, Radhakrishnan, Santoro, Armando, Paszkiewicz-Kozik, Ewa, Gasiorowski, Robin, Johnson, Nathalie A, Fogliatto, Laura Maria, Goncalves, Iara, de Oliveira, Jose S R, Buccheri, Valeria, Perini, Guilherme F, Goldschmidt, Neta, Kriachok, Iryna, Dickinson, Michael, Komarnicki, Mieczyslaw, McDonald, Andrew, Ozcan, Muhit, Sekiguchi, Naohiro, Zhu, Ying, Nahar, Akash, Marinello, Patricia, and Zinzani, Pier Luigi

Published
2021
Full Text
View/download PDF

18. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Author

Morschhauser, Franck, Feugier, Pierre, Flinn, Ian W., Gasiorowski, Robin, Greil, Richard, Illés, Árpád, Johnson, Nathalie A., Larouche, Jean-François, Lugtenburg, Pieternella J., Patti, Caterina, Salles, Gilles A., Trněný, Marek, de Vos, Sven, Mir, Farheen, Samineni, Divya, Kim, Su Y., Jiang, Yanwen, Punnoose, Elizabeth, Sinha, Arijit, Clark, Emma, Spielewoy, Nathalie, Humphrey, Kathryn, Bazeos, Alexandra, and Zelenetz, Andrew D.

Published
2021
Full Text
View/download PDF

19. Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.

Author

Banerji, Versha, Aw, Andrew, Laferriere, Nicole, Abdel-Samad, Nizar, Peters, Anthea, Johnson, Nathalie A., Bernard, Marie-Pierre, Gopalakrishnan, Sathish, Bull, Sarah-Jane, Fournier, Pierre-André, Klil-Drori, Adi J., Hay, Annette E., Robinson, Sue, and Owen, Carolyn

Subjects
CHRONIC lymphocytic leukemia, TUMOR lysis syndrome, VENETOCLAX, MEDICAL care, QUALITY of life, CANADIAN provinces
Abstract

Venetoclax is a first-in-class B-cell lymphoma-2 (BCL-2) inhibitor approved as continuous monotherapy and in combination with rituximab as fixed-treatment duration for relapsed and refractory chronic lymphocytic leukemia (R/R CLL). DEVOTE was a 24-week, multicenter observational study (NCT03310190) evaluating the safety, healthcare resource utilization (HCRU) and health-related quality of life (HRQoL) of patients initiating venetoclax for R/R CLL in Canada. Overall, 89 patients received 1 dose of venetoclax; 80% had prior exposure (42% resistant) to ibrutinib. Biochemical tumor lysis syndrome (TLS) occurred in five patients. We observed differences in hospitalization across Canadian provinces including in patients at low risk for TLS with no clear impact on TLS incidence. Additionally, a rapid and sustained improvement in several domains of HRQoL was observed during venetoclax initiation. Early adoption of venetoclax was mainly for R/R CLL patients with few treatment options; nonetheless, acceptable toxicity and a positive impact on HRQoL were observed. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma

Author

Rushton, Christopher K., Arthur, Sarah E., Alcaide, Miguel, Cheung, Matthew, Jiang, Aixiang, Coyle, Krysta M., Cleary, Kirstie L.S., Thomas, Nicole, Hilton, Laura K., Michaud, Neil, Daigle, Scott, Davidson, Jordan, Bushell, Kevin, Yu, Stephen, Rys, Ryan N., Jain, Michael, Shepherd, Lois, Marra, Marco A., Kuruvilla, John, Crump, Michael, Mann, Koren, Assouline, Sarit, Connors, Joseph M., Steidl, Christian, Cragg, Mark S., Scott, David W., Johnson, Nathalie A., and Morin, Ryan D.

Published
2020
Full Text
View/download PDF

24. mRNA Translation Inhibition Targets Bioenergetic Homeostasis in AML Cells in Vitro and In Vivo and Synergizes with Cytarabine and Venetoclax

Author

Gife, Victor, primary, Fooks, Katie, additional, Berthelemy, Jules, additional, Schcolnik-Cabrera, Alejandro, additional, Galicia-Vazquez, Gabriela, additional, Nouhi, Zaynab, additional, Aloyz, Raquel, additional, Rys, Ryan N, additional, Johnson, Nathalie A., additional, Mercier, Francois E., additional, and Hulea, Laura, additional

Published
2023
Full Text
View/download PDF

27. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

Author

Timmerman, John, primary, Lavie, David, additional, Johnson, Nathalie, additional, Avigdor, Abraham, additional, Borchmann, Peter, additional, Andreadis, Charalambos, additional, Bazargan, Ali, additional, Gregory, Gareth, additional, Keane, Colm, additional, Tzoran, Inna, additional, Vucinic, Vladan, additional, Luigi Zinzani, Pier, additional, Marceau West, Rachel, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Herrera, Alex F., additional

Published
2023
Full Text
View/download PDF

28. P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Author

Johnson, Nathalie, primary, Lavie, David, additional, Borchmann, Peter, additional, Gregory, Gareth, additional, Herrera, Alex F., additional, Minuk, Leonard, additional, Vucinic, Vladan, additional, Armand, Philippe, additional, Avigdor, Abraham, additional, Gasiorowski, Robin, additional, Herishanu, Yair, additional, Keane, Colm, additional, Kuruvilla, John, additional, Marceau West, Rachel, additional, Pillai, Pallavi, additional, Marinello, Patricia, additional, and Timmerman, John, additional

Published
2023
Full Text
View/download PDF

35. Supplementary Figure from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

36. Data from Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

Author

Rubinstein, Samuel M., primary, Bhutani, Divaya, primary, Lynch, Ryan C., primary, Hsu, Chih-Yuan, primary, Shyr, Yu, primary, Advani, Shailesh, primary, Mesa, Ruben A., primary, Mishra, Sanjay, primary, Mundt, Daniel P., primary, Shah, Dimpy P., primary, Sica, R. Alejandro, primary, Stockerl-Goldstein, Keith E., primary, Stratton, Catherine, primary, Weiss, Matthias, primary, Beeghly-Fadiel, Alicia, primary, Accordino, Melissa, primary, Assouline, Sarit E., primary, Awosika, Joy, primary, Bakouny, Ziad, primary, Bashir, Babar, primary, Berg, Stephanie, primary, Bilen, Mehmet Asim, primary, Castellano, Cecilia A., primary, Cogan, Jacob C., primary, KC, Devendra, primary, Friese, Christopher R., primary, Gupta, Shilpa, primary, Hausrath, Daniel, primary, Hwang, Clara, primary, Johnson, Nathalie A., primary, Joshi, Monika, primary, Kasi, Anup, primary, Klein, Elizabeth J., primary, Koshkin, Vadim S., primary, Kuderer, Nicole M., primary, Kwon, Daniel H., primary, Labaki, Chris, primary, Latif, Tahir, primary, Lau, Eric, primary, Li, Xuanyi, primary, Lyman, Gary H., primary, McKay, Rana R., primary, Nagaraj, Gayathri, primary, Nizam, Amanda, primary, Nonato, Taylor K., primary, Olszewski, Adam J., primary, Polimera, Hyma V., primary, Portuguese, Andrew J., primary, Puc, Matthew M., primary, Razavi, Pedram, primary, Rosovski, Rachel, primary, Schmidt, Andrew, primary, Shah, Sumit A., primary, Shastri, Aditi, primary, Su, Christopher, primary, Torka, Pallawi, primary, Wise-Draper, Trisha M., primary, Zubiri, Leyre, primary, Warner, Jeremy L., primary, and Thompson, Michael A., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype

Author

Preston, Samuel E.J., primary, Emond, Audrey, primary, Pettersson, Filippa, primary, Dupéré-Richer, Daphné, primary, Abraham, Madelyn Jean, primary, Riva, Alberto, primary, Kinal, Mena, primary, Rys, Ryan N., primary, Johnson, Nathalie A., primary, Mann, Koren K., primary, del Rincón, Sonia V., primary, Licht, Jonathan D., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

38. Data from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype

Author

Preston, Samuel E.J., primary, Emond, Audrey, primary, Pettersson, Filippa, primary, Dupéré-Richer, Daphné, primary, Abraham, Madelyn Jean, primary, Riva, Alberto, primary, Kinal, Mena, primary, Rys, Ryan N., primary, Johnson, Nathalie A., primary, Mann, Koren K., primary, del Rincón, Sonia V., primary, Licht, Jonathan D., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Data from Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype

Author

Preston, Samuel E.J., primary, Emond, Audrey, primary, Pettersson, Filippa, primary, Dupéré-Richer, Daphné, primary, Abraham, Madelyn Jean, primary, Riva, Alberto, primary, Kinal, Mena, primary, Rys, Ryan N., primary, Johnson, Nathalie A., primary, Mann, Koren K., primary, del Rincón, Sonia V., primary, Licht, Jonathan D., primary, and Miller, Wilson H., primary

Published
2023
Full Text
View/download PDF

40. Supplementary File 1 from Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, primary, Christodoulopoulos, Rosa, primary, Charbonneau, Fredrick, primary, Qureshi, Samia, primary, Rousseau, Caroline, primary, Benlimame, Naciba, primary, Camlioglu, Errol, primary, Constantin, André Marc, primary, Oros, Kathleen Klein, primary, Krumsiek, Jan, primary, Crump, Michael, primary, Morin, Ryan D., primary, Cerchietti, Leandro, primary, Johnson, Nathalie A., primary, Petrogiannis-Haliotis, Tina, primary, Miller, Wilson H., primary, Assouline, Sarit E., primary, and Mann, Koren K., primary

Published
2023
Full Text
View/download PDF

41. Supplementary File 3 from Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, primary, Christodoulopoulos, Rosa, primary, Charbonneau, Fredrick, primary, Qureshi, Samia, primary, Rousseau, Caroline, primary, Benlimame, Naciba, primary, Camlioglu, Errol, primary, Constantin, André Marc, primary, Oros, Kathleen Klein, primary, Krumsiek, Jan, primary, Crump, Michael, primary, Morin, Ryan D., primary, Cerchietti, Leandro, primary, Johnson, Nathalie A., primary, Petrogiannis-Haliotis, Tina, primary, Miller, Wilson H., primary, Assouline, Sarit E., primary, and Mann, Koren K., primary

Published
2023
Full Text
View/download PDF

42. CCR Translation for This Article from BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

Author

Iqbal, Javeed, primary, Meyer, Paul N., primary, Smith, Lynette M., primary, Johnson, Nathalie A., primary, Vose, Julie M., primary, Greiner, Timothy C., primary, Connors, Joseph M., primary, Staudt, Louis M., primary, Rimsza, Lisa, primary, Jaffe, Elaine, primary, Rosenwald, Andreas, primary, Ott, German, primary, Delabie, Jan, primary, Campo, Elias, primary, Braziel, Rita M., primary, Cook, James R., primary, Tubbs, Raymond R., primary, Gascoyne, Randy D., primary, Armitage, James O., primary, Weisenburger, Dennis D., primary, and Chan, Wing C., primary

Published
2023
Full Text
View/download PDF

43. Supplementary File 2 from Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, primary, Christodoulopoulos, Rosa, primary, Charbonneau, Fredrick, primary, Qureshi, Samia, primary, Rousseau, Caroline, primary, Benlimame, Naciba, primary, Camlioglu, Errol, primary, Constantin, André Marc, primary, Oros, Kathleen Klein, primary, Krumsiek, Jan, primary, Crump, Michael, primary, Morin, Ryan D., primary, Cerchietti, Leandro, primary, Johnson, Nathalie A., primary, Petrogiannis-Haliotis, Tina, primary, Miller, Wilson H., primary, Assouline, Sarit E., primary, and Mann, Koren K., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure Legends 1-3, Tables 1-3 from BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

Author

Iqbal, Javeed, primary, Meyer, Paul N., primary, Smith, Lynette M., primary, Johnson, Nathalie A., primary, Vose, Julie M., primary, Greiner, Timothy C., primary, Connors, Joseph M., primary, Staudt, Louis M., primary, Rimsza, Lisa, primary, Jaffe, Elaine, primary, Rosenwald, Andreas, primary, Ott, German, primary, Delabie, Jan, primary, Campo, Elias, primary, Braziel, Rita M., primary, Cook, James R., primary, Tubbs, Raymond R., primary, Gascoyne, Randy D., primary, Armitage, James O., primary, Weisenburger, Dennis D., primary, and Chan, Wing C., primary

Published
2023
Full Text
View/download PDF

45. Supplementary File 5 from Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, primary, Christodoulopoulos, Rosa, primary, Charbonneau, Fredrick, primary, Qureshi, Samia, primary, Rousseau, Caroline, primary, Benlimame, Naciba, primary, Camlioglu, Errol, primary, Constantin, André Marc, primary, Oros, Kathleen Klein, primary, Krumsiek, Jan, primary, Crump, Michael, primary, Morin, Ryan D., primary, Cerchietti, Leandro, primary, Johnson, Nathalie A., primary, Petrogiannis-Haliotis, Tina, primary, Miller, Wilson H., primary, Assouline, Sarit E., primary, and Mann, Koren K., primary

Published
2023
Full Text
View/download PDF

46. Supplementary File 4 from Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, primary, Christodoulopoulos, Rosa, primary, Charbonneau, Fredrick, primary, Qureshi, Samia, primary, Rousseau, Caroline, primary, Benlimame, Naciba, primary, Camlioglu, Errol, primary, Constantin, André Marc, primary, Oros, Kathleen Klein, primary, Krumsiek, Jan, primary, Crump, Michael, primary, Morin, Ryan D., primary, Cerchietti, Leandro, primary, Johnson, Nathalie A., primary, Petrogiannis-Haliotis, Tina, primary, Miller, Wilson H., primary, Assouline, Sarit E., primary, and Mann, Koren K., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figures 1-3 from BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab

Author

Iqbal, Javeed, primary, Meyer, Paul N., primary, Smith, Lynette M., primary, Johnson, Nathalie A., primary, Vose, Julie M., primary, Greiner, Timothy C., primary, Connors, Joseph M., primary, Staudt, Louis M., primary, Rimsza, Lisa, primary, Jaffe, Elaine, primary, Rosenwald, Andreas, primary, Ott, German, primary, Delabie, Jan, primary, Campo, Elias, primary, Braziel, Rita M., primary, Cook, James R., primary, Tubbs, Raymond R., primary, Gascoyne, Randy D., primary, Armitage, James O., primary, Weisenburger, Dennis D., primary, and Chan, Wing C., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table 1 from Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials

Author

Nielsen, Torsten Holm, primary, Diaz, Zuanel, primary, Christodoulopoulos, Rosa, primary, Charbonneau, Fredrick, primary, Qureshi, Samia, primary, Rousseau, Caroline, primary, Benlimame, Naciba, primary, Camlioglu, Errol, primary, Constantin, André Marc, primary, Oros, Kathleen Klein, primary, Krumsiek, Jan, primary, Crump, Michael, primary, Morin, Ryan D., primary, Cerchietti, Leandro, primary, Johnson, Nathalie A., primary, Petrogiannis-Haliotis, Tina, primary, Miller, Wilson H., primary, Assouline, Sarit E., primary, and Mann, Koren K., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table 1 from Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis

Author

Cheung, K-John J., primary, Johnson, Nathalie A., primary, Affleck, Joslynn G., primary, Severson, Tesa, primary, Steidl, Christian, primary, Ben-Neriah, Susana, primary, Schein, Jacqueline, primary, Morin, Ryan D., primary, Moore, Richard, primary, Shah, Sohrab P., primary, Qian, Hong, primary, Paul, Jessica E., primary, Telenius, Adele, primary, Relander, Thomas, primary, Lam, Wan, primary, Savage, Kerry, primary, Connors, Joseph M., primary, Brown, Carolyn, primary, Marra, Marco A., primary, Gascoyne, Randy D., primary, and Horsman, Douglas E., primary

Published
2023
Full Text
View/download PDF

50. Data from Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis

Author

Cheung, K-John J., primary, Johnson, Nathalie A., primary, Affleck, Joslynn G., primary, Severson, Tesa, primary, Steidl, Christian, primary, Ben-Neriah, Susana, primary, Schein, Jacqueline, primary, Morin, Ryan D., primary, Moore, Richard, primary, Shah, Sohrab P., primary, Qian, Hong, primary, Paul, Jessica E., primary, Telenius, Adele, primary, Relander, Thomas, primary, Lam, Wan, primary, Savage, Kerry, primary, Connors, Joseph M., primary, Brown, Carolyn, primary, Marra, Marco A., primary, Gascoyne, Randy D., primary, and Horsman, Douglas E., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results